Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00108836 · ClinicalTrials.gov registry record · Phase 2
Efficacy, Safety and Tolerability of XBD173 in Patients With Generalized Anxiety Disorder
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 400
- Enrollment target
NCT00108836: Completed Phase 2 study, sponsored by Novartis Pharmaceuticals.
NCT00108836 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 400 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (201% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00108836, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 400 participants
- Enrollment target
Study Summary
This study will test the efficacy, safety and tolerability of XBD173 in the treatment of generalized anxiety disorder in patients.
Interventions
- DRUG XBD173
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2005-03 |
| Est. Completion | 2006-05 |
| Phase | Phase 2 |
What the finished NCT00108836 record still lists
NCT00108836 is an interventional study that assigns participants to a tested intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (201% higher).
The record links to 0 conditions, and to 1 intervention - of which XBD173 is the first listed.
NCT00108836 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00108836 about?
NCT00108836 is a clinical study titled "Efficacy, Safety and Tolerability of XBD173 in Patients With Generalized Anxiety Disorder". This study will test the efficacy, safety and tolerability of XBD173 in the treatment of generalized anxiety disorder in patients.
What is the current status of trial NCT00108836?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 400 participants. The study started on 2005-03. Estimated completion is 2006-05.
What interventions are being tested in trial NCT00108836?
The interventions under investigation include: XBD173 (DRUG).
Who is sponsoring clinical trial NCT00108836?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00108836's enrollment target sits among peer trials
400 96th of 2000 higher than 1,898 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
- NCT02216500 · 400 participants · NA
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
- NCT02250352 · 400 participants
Core Biopsies for Establishing a Breast Tumor Tissue Repository
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia